Cargando…
Patented small molecule inhibitors in the ubiquitin proteasome system
Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(®) (bortezomib) for the treatment of multiple myeloma and mantle cell lympho...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2106365/ https://www.ncbi.nlm.nih.gov/pubmed/18047738 http://dx.doi.org/10.1186/1471-2091-8-S1-S14 |